Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21290883 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL5067978 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL8895922 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL20158970 | 0.81 | MAOA (0.40) | ATMGAAPIK3CD | |
| SCHEMBL20158969 | 0.81 | MAOA (0.40) | ATMGAAPIK3CD | |
| SCHEMBL30148983 | 0.81 | MAOA (0.40) | ATMGAAPIK3CD | |
| SCHEMBL17414173 | 0.78 | ATM (0.40) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15478092 | 0.78 | ATM (0.40) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17663642 | 0.78 | ATM (0.40) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24634003 | 0.78 | PIK3CD (0.39) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016050209-A1 | HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| US-20120294843-A1 | CASPASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-11-22 | — | — | US | disclosed |
| EP-1910378-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294843-A1 | CASPASE INHIBITORS | CASP1, CASP7, CASP14 | ATM 2086/4885CHRNB2 4869/4885CHRNA3 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.